Abeona Therapeutics INC

Abeona Therapeutics shareholders elected directors, ratified auditors, and approved an equity plan increase at the 2026 annual meeting.

Abeona Therapeutics Inc. announced the immediate resignation of board member Michael Amoroso for personal reasons.

Abeona Therapeutics has released an updated investor presentation for use in upcoming stakeholder engagements.

Abeona Therapeutics Inc. reports a constructive Pre-IND meeting with the FDA regarding its novel T-cell therapy ABO-701 for prostate cancer, targeting IND submission in 2027.

Abeona Therapeutics reported Q1 2026 results with $8.7M in net product revenue, expanded ZEVASKYN adoption, and in-licensed a novel T-cell therapy for solid tumors.

Abeona Therapeutics expands its board to ten members, appointing industry veteran Keith A. Goldan as Audit Committee Chair to support its commercial-stage growth.

Abeona Therapeutics Inc. reported its first quarter 2026 financial results, highlighting $8.7 million in product revenue from ZEVASKYN and a net loss of $17.1 million.

Abeona Therapeutics reported a significant net income for the nine months ended September 30, 2025, driven by the sale of its ZEVASKYN Priority Review Voucher, despite initial manufacturing challenges for its newly approved gene therapy.

Abeona Therapeutics reported a significant net income increase in Q2 2025, driven by the FDA approval of ZEVASKYN and the subsequent sale of its Priority Review Voucher for $155 million.

Abeona Therapeutics announces its Q1 2025 financial results, emphasizing the FDA approval of ZEVASKYN and the subsequent agreement to sell its Rare Pediatric Disease Priority Review Voucher for $155 million.

Abeona Therapeutics reported its financial results for the third quarter of 2024 and provided an update on the resubmission of its Biologics License Application (BLA) for pz-cel.

Abeona Therapeutics reported its second quarter 2024 financial results, highlighted by a net income of $7.4 million, and provided an update on the resubmission of its Biologics License Application (BLA) for pz-cel.

Abeona Therapeutics Inc. reports FDA approval for ZEVASKYN, generating significant revenue from a Priority Review Voucher sale, while continuing to advance its gene therapy pipeline.

Abeona Therapeutics Inc. files its Form 10-K, detailing the company's financial results, business activities, and progress in developing cell and gene therapies for life-threatening diseases, with a focus on its lead program, pz-cel, for recessive dystrophic epidermolysis bullosa (RDEB).

Abeona Therapeutics emphasizes its commitment to ethical business practices and compliance in its recent 10-K filing, outlining standards for all employees and stakeholders.

Joseph Walter Vazzano, Chief Financial Officer of Abeona Therapeutics Inc., sold 1,478 shares of common stock on July 21, 2026 for $6.53 per share.

Abeona Therapeutics Chief Financial Officer, Joseph Vazzano, reported a sale of 24,880 shares of common stock on July 9, 2026, to cover tax obligations.

Abeona Therapeutics CEO Vishwas Seshadri reported a sale of 67,971 shares of common stock on July 9, 2026, to cover tax obligations from vested stock awards.

Abeona Therapeutics SVP, Chief Legal Officer Brendan O'Malley reported a sale of 12,050 shares of common stock on July 9, 2026, to cover tax obligations.

Abeona Therapeutics Chief Commercial Officer, Vasanthavada Madhav, reported a transaction involving the sale of common stock.

Director Christine Silverstein sold 18,160 shares of Abeona Therapeutics to satisfy tax obligations related to restricted stock vesting.

Abeona Therapeutics Inc. has issued its 2026 proxy statement detailing proposals for director elections, executive compensation, and an increase in equity incentive plan shares.

Abeona Therapeutics will hold its annual stockholders meeting virtually on May 19, 2025, to vote on director elections, executive compensation, and auditor ratification.

Abeona Therapeutics is asking shareholders to approve an increase in the number of shares reserved for issuance under its 2023 Equity Incentive Plan from 3,200,000 to 8,400,000 shares.

Abeona Therapeutics is asking stockholders to approve an increase in shares reserved for issuance under its 2023 Equity Incentive Plan from 1.7 million to 3.2 million shares at the upcoming annual meeting.

Nantahala Capital Management and its principals have reported a 9.99% beneficial ownership stake in Abeona Therapeutics Inc.

Nantahala Capital Partners Limited Partnership has filed a Schedule 13G reporting a 5.82% beneficial ownership stake in Abeona Therapeutics Inc.

AIGH Capital Management and affiliated entities now beneficially own over 5.4% of Abeona Therapeutics' common stock, as disclosed in a Schedule 13G filing.

Funicular Funds, LP, along with Cable Car Capital, LP and Jacob Ma-Weaver, has disclosed beneficial ownership of 3,007,329 shares, representing 5.3% of Abeona Therapeutics Inc.'s common stock.

Individual investor Daniel Kaufman has reported a 5.16% beneficial ownership stake in Abeona Therapeutics Inc., totaling 2,943,629 shares.

The Vanguard Group has reported a complete divestment of its beneficial ownership in Abeona Therapeutics Inc. common stock following an internal corporate realignment.